The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy

Seminars in Cancer Biology

Volumn 9, Issue 2, 1999, Pages 125-138

  Ross, Jeffrey S ^a   Fletcher, Jonathan A ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast neoplasms; HER 2 neu prognosis; Proto oncogene; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HORMONE; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; BREAST TUMOR; CANCER IMMUNOTHERAPY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; MALE; PROGNOSIS; PROTO ONCOGENE; REVIEW; SEQUENCE HOMOLOGY; SOUTHERN BLOTTING; TREATMENT OUTCOME;

EID: 0032992528     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0083     Document Type: Article

References (124)

1. Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors. Science. 240:1988;1795-1798.
2. De Potter CR. The neu oncogene: more than a prognostic indicator. Hum Pathol. 25:1994;1264-1268.
3. Lupu R, Cardillo M, Harris L, Hijaz M, Rosenberg K. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance. Sem Cancer Biol. 6:1995;135-145.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/ neu oncogene. Science. 235:1987;177-182.
5. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfueld MD. Correlation of c- erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48:1988;1238-1243.
6. van de Vivjer MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu -protein overexpression in breast cancer. N Engl J Med. 319:1988;1239-1245.
7. Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c- erb B-2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med. 114:1990;160-163.
8. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of. 176:1990;65-794.
9. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killande r D, McGuire WL. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50:1990;4332-4337.
10. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinge r J, Lippman ME, King CR. Pathologic findings from the nations surgical adjuvant breast and bowel project: Prognostic significance of erb B2 protein overexpression in primary breast cancer. J Clin Oncol. 8:1990;103-112.
11. Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Faucett C, Niland J. Immunohistochemical assay of neu/ c- erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases. Modern Pathol. 4:1991;466-474.
12. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 49:1991;650-655.
13. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 51:1991;944-948.
14. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gu llick WJ, Elston CW, Blamey RW. C-erb B2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 63:1991;439-443.
15. McCann AH, DeDervan TA, O'Regan M, Codd MB, Gullick WJ, Tobin BM, Carney DN. Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer. Cancer Res. 51:1991;3296-3303.
16. Dykens R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, Lennard TJ, Angus B, Horne CH. Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol. 163:1991;105-110.
17. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 49:1991;44-49.
18. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS. The long term prognostic significance of C-erb B2 in primary breast cancer. Br J Cancer. 63:1991;447-450.
19. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer. Br J Cancer. 63:1991;444-446.
20. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA. Correlation between C-erb B2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 51:1991;556-567.
21. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up. J Clin Oncol. 10:1992;1044-1048.
22. Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM. Expression of HER-2/neu oncoprotein in breast cancer: A comparison of immunohistochemical and western blot techniques. Anticancer Res. 12:1992;1965-1991.
23. Noguchi M, Koyasaki M, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y. c- erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer. 69:1992;2953-2960.
24. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L. HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol. 10:1992;599-605.
25. Babiak J, Hugh J, Poppeme S. Significance of c- erb B-2 amplification in DNA aneuploidy. Analysis in. 78:1992;70-70.
26. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. HER-2/ neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12:1992;419-426.
27. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golough R, Reed R. Prognostic importance of C-erb B2 expression in breast cancer. J Clin Oncol. 10:1992;1049-1056.
28. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S. Prognostic significance of C-erb B2 expression in node negative breast cancer. Br J Cancer. 67:1993;625-629.
29. Press MF, Pike MC, Chazin VR, Hung G, Udove JA Markowicz M, Danyluk J, Gololphin JW, Sliwkowski M, Akita R. Her-2/ neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:1993;4960-4970.
30. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Stelur V, Kitchen P. Clinical sign ificance of Her-2/ neu oncogene amplification in primary breast cancer. J Clin Oncol. 11:1993;1936-1942.
31. Descotes F, Pavy J-J, Adessi GL. Human breast cancer: Correlation study between Her-2/ neu amplification and prognostic factors in an unselected population. Anticancer Res. 13:1993;119-124.
32. Giai M, Roagna R, Ponzone R, deBortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of C-erb B2 and ras expression in node positive and negative breast cancer. Anticancer Res. 14:1994;1441-1450.
33. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC Barcos M. Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 330:1994;1260-1266.
34. Tetu B, Brisson J. Prognostic significance of Her-2/ neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer. 73:1994;2359-2365.
35. Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC. Prognostic value of CerbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer. 74:1994;2956-2963.
36. Jacquemier J, Penault-Llorca P, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adelaide J, Birnbaum D. Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression. Anticancer Res. 14:1994;2773-2778.
37. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Ingleha rt JD. Overexpression of p53 and Her-2/ neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 219:1994;332-341.
38. Rosen PP, Lesser ML. Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of Her-2/ neu expression in patients with axillary lymph node-negative breast carcinoma. A study of epidemiologic risk factors, histologic features and prognosis. Cancer. 75:1995;1320-1326.
39. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 35:1995;283-291.
40. Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic expression in stages I and II breast cancer; its relationship with clinicopathologic factors. Hum Pathol. 27:1996;297-300.
41. O'Malley FP, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, Hundal H, Chambers AF, Turnbull DI, Bramwell V. The predictive power of semiqu antitative immunohistochemical assessment of p53 and C- erbB 2 in lymph node-negative breast cancer. Hum Pathol. 27:1996;955-963.
42. Hieken TJ, Mehta RR, Shilkaitis A, Wild LD, Das Gupta TK. Her-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry. Proc Annu Meet Am Soc Clin Oncol. 15:1996;A113.
43. Xing W-R. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat. 39:1996;203-212.
44. Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A, Gion M. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res. 17:1997;1245-1247.
45. Fernandez Acanero MJ, Farina Gonzalez J, Arangoncillo Ballesteros P. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol. 142:1997;289-296.
46. Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res. 17:1997;3091-3097.
47. Charpin C, Garcia S, Bouvier C, Martini F, Lavault MN, Allasia C, Bonnier P, Andrac L. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer. 75:1997;1667-1673.
48. Press MJ, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. Her-2/ neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 15:1997;2894-2904.
49. Ross JS, Muraca PJ, Jaffe D, Morgan T, Fletcher JA. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol. 11:1998;26A.
50. cdc2cyclin dependent kinase and MIBI overexpression, and HER-2/ neu gene amplification detected by fluorescence in-situ hybridization in breast cancer. Mod Pathol. 11:1998;18A.
51. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol. 15:1991;334-349.
52. Porter-Jordan K, Lippman ME. Overview of the biologic markers in breast cancer. Hematol Oncol Clin North Am. 8:1994;73-100.
53. McGuire WL, Tandon AK, Allred DC. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst. 82:1990;1006-1015.
54. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/ neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 13:1996;63-72.
55. Sauter G, Feichter G, Torhorst J, Moch H, Novotna H, Wagner U, Durmuller U, Waldman FM. Fluorescence in-situ hybridization for detecting ERBB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol. 40:1996;164-173.
56. Allred DC, Harvey JM, Berardo M, Calrk GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:1998;155-168.
57. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 88:1996;1054-1059.
58. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation. J Pathol. 173:1994;65-75.
59. Busmanis I, Feleppa F, Jones A, McGrath KM, Reed R, Collins J, Russell I, Begley CG. Analysis of C-erb B2 expression using a panel of six commercially available antibodies. Pathology. 26:1994;261-267.
60. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of Her-2/ neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54:1994;2771-2777.
61. vanDiest PJ, vanDam P, Henzen-Logmans SC, Berns E, van der Burg ME, G reen J, Vergote I. A scoring system for immunohistochemical staining: Consensus report of the Task Force for Basic Research of the EORTC-GCGC. J Clin Pathol. 50:1997;801-804.
62. Lodato RF, Maguire HC, Greene MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c erb B2 oncogene expression in ductal carcinoma in-situ and atypical ductal hyperplasia of the breast. Modern Pathol. 3:1990;449-454.
63. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Overexpression of Her-2/ neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer. Hum Pathol. 23:1992;974-979.
64. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X. mammographically- detected ductal in-situ carcinoma of the breast analyzed with a new classification. Sem Diagn Pathol. 11:1994;208-214.
65. Brower FT, Ahmed S, Tartter P, Bleiweiss I, Amberson JB. Prognostic variables in invasive breast cancer: Contribution of comedo versus non-comedo in-situ component. Ann Surg Oncol. 2:1995;440-444.
66. Leal CB, Schmitt FC, Bento MJ, Maia MC, Lopes CS. Ductal carcinoma in-situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and C erb B-2 protein. Cancer. 75:1995;2123-2131.
67. Bobrow WLG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in-situ: Assessment of necrosis in nuclear morphology and their association with biological markers. J Pathol. 176:1995;333-341.
68. De Potter CR, Schelhout AM, Verbeeck P, Lakhani SR, Brunken R, Schroeter CA, Van den Tweel JG, Schauer AJ, Sloane JP. neu overexpression corre lates with extent of disease in large cell ductal in situ carcinoma of the breast. Hum Pathol. 26:1995;601-606.
69. Inaji H, Koyama H, Motomura K, Noguchi S. Differential distrib ution of erb B2 and pS2 proteins in ductal carcinoma in-situ of the breast. Breast Cancer Res Treat. 37:1996;89-92.
70. Albonico G, Querzoli P, Ferretti S, Magri E, Nenci I. Biophenotypes of breast carcinoma in-situ defined by image analysis of biological parameters. Pathol Res Pract. 192:1996;117-123.
71. Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med. 120:1996;81-85.
72. Moreno A, Lloveras B, Figueras A, Escobedo A, Ramon JM, Sierra A, Fabra A. Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers. Mod Pathol. 10:1997;1088-1092.
73. Mack L, Kerkzelit N, Doig G, O'Malley FP. Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67. Human Pathol. 28:1997;974-979.
74. Porter PL, Garcia R, Moe R. c erb B2 oncogene protein in in-situ and invasive lobular breast neoplasia. Cancer. 68:1991;331-334.
75. Wolber RA, DuPuis BA, Wick MR. Expression of c erb B2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol. 96:1991;243-247.
76. Lilleng R, Hagmar BM, Nesland JM. c erb B2 protein and neuroendocrine expression in intraductal carcinomas of the breast. Modern Pathol. 5:1992;41-47.
77. Yeh I-T, Keykhah S, Selig AM. Expression of erb B2 gene in the benign and proliferative breast tissue. Surg Pathol. 5:1993;109-120.
78. Hanna W, Kahn HJ, Andrulis I, Pawson T. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Modern Pathol. 3:1990;455-461.
79. Odagiri E, Kanada N, Jibiki K, Demura R, Aikawa E, Demura H. Reduction of Telomeric-linked c erb B2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer. 73:1994;2978-2984.
80. Gattuso P, Reddy VB, Green LK. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol. 2:1995;199-206.
81. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome. Cancer. 77:1996;490-498.
82. Willsher PC, Leach IH, Ellis IO, Bell JA, Elston CW, Bourke JB, Blamey RW, Robertson JF. Male breast cancer: Pathological and immunohistochemical features. Anticancer Res. 17:1997;2335-2338.
83. Bines J, Goss B, Hussong J. C-erb and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Annu Assoc Clin Oncol. 16:1997;A558.
84. Bruce DM, Heys DD, Payne S, Miller ID, Eremin O. Male breast cancer: Clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol. 22:1996;42-46.
85. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Modern Pathol. 5:1992;621-625.
86. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH. Relationship between C-ERBB 2 protein product expression and response to endocrine therapy in advanced to breast cancer. Br J Cancer. 65:1992;118-121.
87. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers LM, Lipton A. Elevated serum C-erb B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 13:1995;1129-1135.
88. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene. 159:1995;11-18.
89. Stahl O, Sullivan S, Wingren S. C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 31:1995;2185-2190.
90. Archer SG, Eliopoulis SA, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF. Expression of ras p21, p53 and C-erb B2 in advanced breast cancer and response to line hormonal therapy. Br J Cancer. 72:1995;1259-1266.
91. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 13:1996;1359-1365.
92. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S. CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol. 14:1996;2702-2708.
93. Haffty BG, Brown F, Carter D, Flynn S. Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Rad Oncol, Biol, Phys. 35:1996;751-757.
94. Revilllion F, Hebbar M, Boneterre J, Peyrat JP. Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients. Eur J Cancer. 32:1996;231-234.
95. Baselga J, Seidman AD, Rosen PP, Norton L. HER-2 overexpression and paclitazel sensitivity in breast cancer: therapeutic implications. Oncology. 11:1997;43-48.
96. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15:1997;537-547.
97. Newby JC, Johnston SRD, Smith IE. Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 3:1997;1643-1651.
98. Burke HB, Hoang A, Iglehart JD, Marks JR. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer. 82:1998;874-877.
99. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 15:1997;2518-2525.
100. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncology group study. Clin Cancer Res. 4:1998;7-12.
101. Bianco AR, De Laurentiis M, Carlomagno C. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc ASCO. 17:1998;97a.
102. Ravdin PM, Green S, Albain V. Initial report of the SWOG biological correlative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone. Proc ASCO. 17:1998;97a.
103. Isola JJ, Holli K, Oksa H, Teramoto Y, Kallionemi OP. Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer. Cancer. 73:1994;652-658.
104. Kandl H, Seymour L, Bezwoda WR. Soluable c- erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer. 70:1994;739-742.
105. Wu JT, Astill ME, Gagon SD, Bryson L. Measurement of C-erb B2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: Correlation with serum tumor markers and membrane-bound oncoproteins. J Clin Lab Anal. 9:1995;151-165.
106. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of C-erb B2 related proteins in sera from breast cancer patients. Relationship to ERBB. 2:1995;2-4.
107. Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A. Serial serum C-erbB-2 levels in patients with breast carcinoma. Cancer. 78:1996;267-272.
108. Molina R, Jo J, Vanon G, Filella X, Farrus B, Munoz M, Latre ML, Pahisa J, Velasco M, Fernandez P, Estape J, Ballesta M. Utility of cerbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA15. Tumor Biol. 3:1996;74-126.
109. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blamey RW, Robertson JF. Prognostic significance of serum CerbB2 protein in breast cancer patients. Breast Cancer Res Treat. 40:1996;251-255.
110. Fehm T, Maimonis P, Wetz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat. 43:1997;87-95.
111. Mansour OA, Zekri AR, Harvey J, Teramoto Y, El-Ahmady O. Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: Three years follow-up. Anti Cancer Res. 17:1997;3101-3106.
112. Shepard HM, Lewis GD, Sarup JC, Fendley BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A. Monoclonal antibody therapy of human cancer: taking the Her-2 proto-oncogene to the clinic. J Clin Immunol. 11:1991;117-127.
113. Zhang L, Chang C, Bacus SS, Hung MC. Suppressed transformation and induced differentiation of Her-2/ neu - overexpressing breast cancer cells by emodin. Cancer Res. 55:1995;3890-3896.
114. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M. Phase Ia/Ib trial o f bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol. 13:1995;2281-2292.
115. Jinno H, Ueda M, Enomoto K, Ikeda T, Kyriakos P, Kitajima M. Effectiveness of an adriamycin immunoconjugate that recognizes the CerbB2 product on breast cancer cell lines. Surg Today. 26:1996;501-507.
116. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti p185 Her-2 monoclonal antibody in patients with Her-2/ neu overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
117. Liu X, Pogo BG. Inhibition of erbB2 positive breast cancer cell growth by erbB2 antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 6:1996;9-16.
118. Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegel GP, Curiel DT. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 4:1997;317-322.
119. Heijnen IA, Buhring HJ, Deo YN, Kalden JR, Gramattzki M, van de Winkel JD. The clinical studies with Fc (Gamma) R by specific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpression in breast cancer. Cancer Res. 57:1997;696-701.
120. Witters LM, Kumar R, Chinchilli VM, Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat. 42:1997;1-5.
121. ®(huhamnized anti-human HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc ASCO. 17:1998;97a.
122. ®(huhamnized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc ASCO. 17:1998;98a.
123. Brossart P, Stuhler J, Flad P, Stevanovic S, Rammensee HJ, Kanz L, Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:1998;732-736.
124. Disis ML, Grabstein KH, Cheaver MA. HER-2/neu peptide vaccines ellicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. Proc ASCO. 17:1998;97-38.